Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 8,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

NCT04635800
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Pediatric Second Influenza Dose Portal Reminder Recall

NCT04668417
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link, Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months to 36 Months
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 4 Interventional Results available

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

NCT00395018
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Chicago, Illinois • New Orleans, Louisiana • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1

NCT00094315
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Cocaine (IV)
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

NCT04585789
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FGF21 and Fructose Challenge in Humans

NCT02884791
View directory record Official record
Conditions
Fasting
Interventions
oral carbohydrate challenge
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism of Ornithine Phenylacetate

NCT03159390
View directory record Official record
Conditions
Healthy
Interventions
phenylacetate salt of ornithine
Other
Lead sponsor
Texas A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT01306617
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
Interventions
ABT-450, ABT-333, ribavirin, ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 22, 2026, 10:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Imaging of Regional Variation in Insulin Sensitivity of Adipose Tissue in Humans

NCT00222768
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 22, 2026, 10:16 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT05470491
View directory record Official record
Conditions
HIV, Hematologic Malignancies
Interventions
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 10:16 PM EDT
Completed No phase listed Observational

Cervical Cancer Early Endpoints and Determinants

NCT00339989
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial, Neoplasia, CIN
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
3,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults

NCT01717950
View directory record Official record
Conditions
Hookworm Infection, Hookworm Disease
Interventions
Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 22, 2026, 10:16 PM EDT
Withdrawn No phase listed Observational

Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

NCT04142398
View directory record Official record
Conditions
HIV Infection, Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Cytology Specimen Collection Procedure, High Resolution Anoscopy with Biopsy, Laboratory Biomarker Analysis, Medical Examination, Physical Examination, Questionnaire Administration
Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 22, 2026, 10:16 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain

NCT03849963
View directory record Official record
Conditions
Brain Metabolism
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001, ACZ885, CJM112, TMT212, EGF816
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

NCT02216409
View directory record Official record
Conditions
Solid Tumor
Interventions
Hu5F9-G4
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 22, 2026, 10:16 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of GH and Lirglutide on AgRP

NCT05681299
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

NCT02194998
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis C Virus and the Humoral Immune System

NCT00219999
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
Not listed
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 4 Interventional

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

NCT00207363
View directory record Official record
Conditions
Hepatitis C
Interventions
Ribavirin, Peg interferon alfa 2b, induction therapy
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

NCT00000999
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18850 - Human Photoallergy Test

NCT02751463
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreening Sport Spray Rest (BAY987519), Untreated skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 22, 2026, 10:16 PM EDT